Ozmosi | BB-025 Drug Profile
Contact Us
Drug Profile
Using advanced filters...
Advanced Search [+]

BB-025

Alternative Names: BB-025, BB 025, BB025
Clinical Status: Active
Latest Update: 2026-04-06
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Unknown

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Basking Biosciences
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BB-025

Countries in Clinic: Australia

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Ischemic Stroke

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT07202663

 BB-CLIN-102

P1

Completed

Ischemic Stroke

2026-03-18

12%

2026-04-07

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

Recent News Events

Date

Type

Title

11/12/2025

News Article

 Basking Biosciences Announces First Participants Dosed in Phase 1 Study of BB-025, a Direct-Acting Reversal Agent for Investigational Stroke Therapy BB-031

10/22/2025

News Article

 Basking Biosciences Doses First Patients in Part B of Phase 2 Stroke Trial, Unlocks $27.5 Million Financing Tranche, and Appoints Julia C. Owens, Ph.D. as Chief Executive Officer

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions